Health Assessment Questionaire Research Articles

Pilates method in the treatment of patients with Chikungunya fever: a randomized controlled trial

Objective: The aim of this study was to evaluate the effects of the Pilates method on the reduction of pain, improvement of joint function, and quality of life of patients with chronic Chikungunya fever. Design: This is a randomized, controlled, blind trial for the evaluators. Setting: The study was conducted at the Advanced Laboratory in Physical Education and Health at Federal University of Pernambuco, Brazil. Subjects: A total of 51 patients were allocated randomly and divided into 2 groups: a Pilates group (26 patients) and a control group (25 patients). After 12 weeks, 4 patients in the Pilates group and 5 in the control group were lost to follow-up. Intervention: The Pilates group performed 24 Pilates method intervention sessions; the control group continued to receive standard clinical treatment at the outpatient clinic. Main measures: The main measures were as follows: visual analogue scale (VAS) for pain, functional capacity evaluated by Health Assessment Questionaire (HAQ), quality of life measured by the 12-Item Short-Form Health Survey (SF-12), and range of joint motion by goniometry. Results: After 12 weeks, patients in the Pilates group presented lower VAS (P < 0.001), lower HAQ scores (P < 0.001), and higher quality-of-life scores (P < 0.001) compared with the control group. We found statistically significant results for the Pilates group in the range of movement for shoulder, knee, ankle, and lumbar spine (P < 0.001). In the intragroup analysis, there was a significant improvement in all outcomes evaluated. Conclusion: In this study, patients undertaking Pilates method for 12 weeks had less pain, better function and quality of life, and increased range of joint movement.

Potential value of serum progranulin as an activity biomarker in rheumatoid arthritis patients: Relation to musculoskeletal ultrasonographic evaluation

Aim of the workTo determine the serum progranulin levels in rheumatoid arthritis (RA) patients and to study its relation with disease activity assessed clinically and by ultrasound (US). Patients and methodsThe study included 52 RA patients and 19 age and sex matched controls. Disease activity score (DAS-28) and modified health assessment questionaire were assessed. Progranulin was measured by ELISA. Ultrasound examination was performed and the German US7 score (USS) recorded. ResultsThe patients mean age was 42.8 ± 10.5 years; disease duration was 4.9 ± 5.02 years; 47 females and 5 males with a mean DAS28 of 4.4 ± 0.9 (3 in remission; 5 low activity; 31 moderate and 13 high). The mean serum progranulin level in patients (9.5 ± 45.5 ng/ml) was significantly elevated compared to control (32.74 ± 9.2 ng/ml) (p < 0.0001). There was a significant difference in the progranulin levels and USS according to the grades of disease activity (p < 0.0001 and p = 0.037 respectively). The progranulin and USS significantly correlated with the DAS28 (r = 0.64, r = 0.58; p < 0.0001 respectively) and erythrocyte sedimentation rate (p < 0.0001). The progranulin and USS significantly correlated with each other (r = 0.32, p = 0.02). At a cut-off value 51.5 ng/ml, progranulin would discriminate between patients and control at sensitivity 96.2%, specificity 100% and accuracy 99%. ConclusionSerum progranulin levels were higher in RA patients than age and sex matched controls. It significantly correlated with disease activity measured by DAS28, ESR and ultrasound activity measured by German US7 score. Serum progranulin levels may be a useful biomarker in RA disease. Ultrasound correlated with ESR and DAS28 in RA patients.

AB1169-HPR The Relationship between Pain and Health-Related Quality of Life in Patients with Juvenile-Onset Systemic Lupus Erythematosus

BackgroundJuvenile-onset systemic lupus erythematosus (JSLE) is an autoimmune disorder with multisystem involvement, leading to inflammatory damage to the joints, kidney, central nervous system, and hematopoietic system affecting children and adolescents....

Estandarización de la versión Peruana del Índice de Incapacidad Funcional del Cuestionario de Evaluación de Salud (Health Assesment Questionnaire - HAQ)

Objetivo: Estandarizar la versión peruana del Índice de Incapacidad Funcional del Cuestionario de Evaluación de salud [Health Assessment Questionaire (HAQ)] en pacientes de 3 hospitales de Lima – Perú. Material y Métodos: A 41 pacientes con artritis Reumatoide, según los criterios del colegio americano de Reumatología se les aplicó el HAQ, para medir el grado de incapacidad funcional {Incapacidad referida (Ir)} y se comparó con una observación directa de 12 actividades {Incapacidad observada (Io)}. Análisis Estadístico: Con el coeficiente de correlación de Pearson entre la Ir y la Io. Resultado: El promedio del Cuestionario fue 0,50 (Escala de 0-3) rango de 0,00 a 1,87, el resultado promedio de la observación directa fue 0,45 (0,00 – 1,58) (r=0,86, p&amp;lt;0,0001). Conclusión: La buena correlación entre lo referido y lo observado, hace que el HAQ – versión Peruana deba ser aplicado a un número mayor de pacientes y por un período más prolongado para confirmar esta validación.

Activity impairments in adult patients with Ehlers–Danlos hypermobility type; the importance of pain and psychological factor

Activity impairments in adult patients with Ehlers–Danlos hypermobility type; the importance of pain and psychological factor

THU0554 Factors of Activity Impairments in Adult Patients with Ehlers Danlos (Hypermobile Type): Muscle Strength and Proprioception

BackgroundPatients with Ehlers Danlos(hypermobility type)(EDS-HT) are characterized by connective tissue laxity which is associated with joint pain and muscle weakness, potentially leading to activity impairment. An important goal during rehabilitation...

AB0798 Is pain a main factor of activity impairments in adult patients with ehlers danlos hypermobility type?

BackgroundEhlers Danlos Syndrome, hypermobility type(EDS-HT) is characterized by overall connective tissue laxity and associated with chronic pain, fatigue and subsequent disability. Literature reports that EDS-HT also has profound effects on...

SAT0153 Early response to infliximab therapy predicts long-term disease activity outcomes in patients with rheumatoid arthritis: Results from the czech national biological therapy registry (ATTRA)

BackgroundInfliximab is well-established tumor necrosis factor α inhibitor in management of rheumatoid arthritis (RA). It has shown efficacy in many randomized controlled clinical trials and registries.ObjectivesTo assess the efficacy of...

AB0220 Translation, cultural adaptation and the reproducibility of the oxford shoulder score questionnaire for brazil

ObjectivesTo translate, perform a cultural adaptation and to test the reproducibility of the Oxford Shoulder Score version for Brazil.MethodsFirst, the Oxford Shoulder Score (OSS) was translated into Portuguese by two...

FRI0475-HPR Comparison the effect to the lower extremity functions of strengthening exercises and proprioceptive-balance exercises in juvenile idiopathic arthritis

BackgroundJuvenile idiopathic arthritis (JIA) is the most common chronic pediatric rheumatic disease and an important cause of acquired impairment and disability in children and adolescents (1). Patients with JIA commonly...

Isokinetic ankle plantarflexion and dorsiflexion strength in patients with rheumatoid arthritis

Backgroud and objectives: In patients with rheumatoid arthritis (RA), some muscle groups are affected in different stages of disease, especially those related to the affected joint. However, data on associations between functional performance and muscle strength in RA are few. Therefore we sought to determine whether isokinetic ankle plantarflexion (PF) and dorsiflexion (DF) strength was affected in RA patients and to study the association between isokinetic strength and other clinical indicators of disability such as walking and stair-climbing time and disease activity in patients with RA. Methods: Thirty three patients diagnosed with RA in the chronic phase were selected from a rheumatology outpatient clinic and matched for age and gender with 33 healthy subjects. Isometric and isokinetic muscle strength was measured in DF and PF. The subjects were also evaluated through the Stanford Health Assessment Questionaire (HAQ), walking and stair-climbing time. Cumulative and current steroid doses (CSD) were calculated. Results: No significant correlations were found between muscle strength and visual analogue scale (VAS) scores, HAQ, ankle involvement, CSD ( p> 0.05). With respect to the isokinetic parameters, no differences have been been observed between RA and control groups ( p> 0.05). Walking and stair-climbing time increased significantly ( p< 0.05) in patients with RA. Conclusions: Ankle isokinetic muscle strength is not affected in inactive RA patients while negative effects of steroids on muscle strength were not demonstrated. Important determinators of walking ability in RA patients should be defined in future studies.

Adalimumab in clinical practice. Outcome in 70 rheumatoid arthritis patients, including comparison of patients with and without previous anti-TNF exposure

To assess the efficacy and safety of the fully human recombinant monoclonal anti-TNF antibody adalimumab in routine clinical practice, including comparison of patients with and without previous anti-TNF exposure. We prospectively studied the outcome of 70 rheumatoid arthritis patients treated with adalimumab in normal clinical practice. The primary outcome measures were Disease Activity Score 28 (DAS28), EULAR (European League Against Rheumatism) response and Health Assessment Questionaire (HAQ). Seventy-seven per cent achieved a EULAR response (26% good, 51% moderate) and 19% were in remission. The mean decrease in DAS28 was 2.1 (6.3-4.2; P<0.001). The mean decrease in HAQ score was 0.34 (2.07-1.73; P<0.001), 66% achieving a clinically significant decrease of greater than 0.22. Twenty-three per cent stopped treatment because of side-effects (7%) or failure to respond (16%). Of the 26 patients who had previously tried 29 biologicals, 65% responded to adalimumab. There was no significant difference in the change in mean DAS (P = 0.69) or HAQ (P = 0.88) between groups with and without previous anti-TNF exposure. Of the 13 patients with previous secondary failure to infliximab, 77% responded to adalimumab. Patients with previous secondary failure had significantly better improvement in DAS (P = 0.023) than patients with previous primary failure. Our clinical experience confirms that adalimumab is effective and safe in the treatment of RA. It also shows adalimumab is effective in patients with previous biological failures, particularly patients with secondary failure to infliximab.